SLN files 8-K with Q3 2025 results and business highlights

Rhea-AI Filing Summary

Silence Therapeutics plc furnished an 8-K to announce it issued a press release with financial results for the third quarter ended September 30, 2025, along with recent business highlights. The press release is provided as Exhibit 99.1 and is incorporated by reference. The information under Item 2.02 is furnished and not deemed filed under the Exchange Act.

The company’s American Depositary Shares trade on Nasdaq under SLN, with each ADS representing 3 ordinary shares of nominal value £0.05 per share.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

falsetrue00014796158-K00-000000000014796152025-11-062025-11-060001479615us-gaap:CommonStockMember2025-11-062025-11-060001479615dei:AdrMember2025-11-062025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2025

Silence Therapeutics plc

(Exact name of Registrant as Specified in Its Charter)

England and Wales	001-39487	Not Applicable
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
12 Hammersmith Grove London United Kingdom		W6 7AP
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: +44 20 3457 6900

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
American Depositary Shares, each representing 3 ordinary shares, nominal value £0.05 per share		SLN		The Nasdaq Stock Market LLC
Ordinary share, nominal value £0.05 per share*		*		The Nasdaq Stock Market LLC

* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2025, Silence Therapeutics plc (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2025, as well as recent business highlights. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated by reference.

The information in this Item 2.02 of this Current Report on 8-K, including Exhibits 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release dated November 6, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		SILENCE THERAPEUTICS PLC
Date: November 6, 2025		By:	/s/ Craig Tooman
			Name: Craig Tooman
			Title: President and Chief Executive Officer (Principal Executive Officer)

FAQ

What did SLN disclose in this 8-K?

The company furnished a press release announcing financial results for the third quarter ended September 30, 2025, and recent business highlights.

Where can I find the detailed Q3 2025 results for SLN?

They are included in the press release attached as Exhibit 99.1.

Is the information in the SLN 8-K considered filed?

No. The Item 2.02 information is furnished and not deemed filed under the Exchange Act.

What is SLN’s Nasdaq trading symbol and security?

SLN’s American Depositary Shares trade on Nasdaq under SLN.

What is the ADS-to-ordinary share ratio for SLN?

Each American Depositary Share represents 3 ordinary shares of nominal value £0.05 per share.

What exhibits are included with the SLN 8-K?

The filing includes Exhibit 99.1 (press release) and Exhibit 104 (Cover Page Interactive Data File).